X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA AUROBINDO PHARMA ELDER PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x -0.2 14.3 - View Chart
P/BV x 0.1 3.7 2.8% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ELDER PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
AUROBINDO PHARMA
Mar-17
ELDER PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs380895 42.5%   
Low Rs188622 30.2%   
Sales per share (Unadj.) Rs491.2254.6 192.9%  
Earnings per share (Unadj.) Rs-3.239.3 -8.1%  
Cash flow per share (Unadj.) Rs14.446.6 30.9%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs376.5160.0 235.4%  
Shares outstanding (eoy) m20.54585.88 3.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.63.0 19.4%   
Avg P/E ratio x-89.319.3 -462.2%  
P/CF ratio (eoy) x19.716.3 121.0%  
Price / Book Value ratio x0.84.7 15.9%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m5,833444,390 1.3%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m2,17917,678 12.3%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m10,089149,157 6.8%  
Other income Rs m2571,159 22.1%   
Total revenues Rs m10,346150,316 6.9%   
Gross profit Rs m-79234,343 -2.3%  
Depreciation Rs m3614,276 8.4%   
Interest Rs m2,756667 413.1%   
Profit before tax Rs m-3,65330,558 -12.0%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1257,597 1.6%   
Profit after tax Rs m-6523,012 -0.3%  
Gross profit margin %-7.823.0 -34.1%  
Effective tax rate %-3.424.9 -13.8%   
Net profit margin %-0.615.4 -4.2%  
BALANCE SHEET DATA
Current assets Rs m9,24092,062 10.0%   
Current liabilities Rs m9,99866,223 15.1%   
Net working cap to sales %-7.517.3 -43.4%  
Current ratio x0.91.4 66.5%  
Inventory Days Days46106 43.7%  
Debtors Days Days6068 88.6%  
Net fixed assets Rs m10,12462,919 16.1%   
Share capital Rs m206586 35.1%   
"Free" reserves Rs m5,58293,133 6.0%   
Net worth Rs m7,73493,719 8.3%   
Long term debt Rs m4,8891,814 269.5%   
Total assets Rs m22,882162,494 14.1%  
Interest coverage x-0.346.8 -0.7%   
Debt to equity ratio x0.60 3,266.1%  
Sales to assets ratio x0.40.9 48.0%   
Return on assets %11.814.6 80.7%  
Return on equity %-0.824.6 -3.4%  
Return on capital %22.332.7 68.1%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30775,838 0.4%   
Fx outflow Rs m12530,224 0.4%   
Net fx Rs m18145,613 0.4%   
CASH FLOW
From Operations Rs m11,75432,786 35.9%  
From Investments Rs m-561-17,870 3.1%  
From Financial Activity Rs m-6,762-19,153 35.3%  
Net Cashflow Rs m4,432-4,239 -104.6%  

Share Holding

Indian Promoters % 39.6 54.1 73.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 8.0 94.3%  
FIIs % 16.8 27.7 60.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 10.2 353.9%  
Shareholders   16,479 69,601 23.7%  
Pledged promoter(s) holding % 77.6 8.6 906.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS